Over the past four years, many of us have become accustomed to a swab up the nose to test for COVID-19, using at-home rapid antigen tests or the more accurate clinic-provided PCR tests with a longer ...

The COVID-19 pandemic yielded important advances in testing for respiratory viruses, but it also exposed important unmet needs in screening to prevent the spread of infections in high-risk settings.

These tests have very limited clinical use. The need for antibody testing would be to determine if a patient has recovered from COVID-19, and whether we could take a sample of the patient’s plasma to ...

Because of its high accuracy, laboratory-based polymerase chain reaction (PCR) testing is the gold standard for infectious disease diagnostics. However, PCR technology requires highly trained staff ...

Real-time PCR enables faster Mycoplasma detection to meet rigorous cell therapy safety standards and reduce quality control-related workflow delays. Cell therapy innovation is accelerating, but ...

Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced ...

A new biotechnology company in McKinney has ambitions to become the world's first fully integrated platform for polymerase chain reaction (PCR) testing - the same technology behind a common COVID-19 ...

Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented ...

The Democratic Republic of Congo has improved its capacity for PCR testing. But it may not be enough to keep up with a rapidly expanding outbreak, and there are no approved rapid tests yet.

Over the past four years, many of us have become accustomed to a swab up the nose to test for COVID-19, using at-home rapid antigen tests or the more accurate clinic-provided PCR tests with a longer ...